Divergent Progress For Chinese Developers Of COVID Antivirals, Vaccines

Factors Include Demand, New Strains

Some of China's makers of COVID-19 antivirals are fast-tracking neutralizing antibodies and peptide fusion inhibitors in clinical trials, while vaccine developers are embroiled in a tougher situation against the mutating coronavirus.

covid therapies hitting FDA wall
Chinese developers of COVID antivirals and vaccines trying hard to tackle mutating coronavirus • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

More from China

More from Focus On Asia